Partner Perspectives: IMC

The OLIP interns were delighted to meet with Innovative Medicines Canada (IMC) and learn more about this new partner of the programme. We had the opportunity to speak with Jacqueline Dobson, Director of Government Affairs; Agata Stankiewicz, Senior Director of Government Relations; and Alex Wellstead, Director of Public Affairs and Government Relations at Novartis, a member company of IMC. 

Over the course of our conversation, we discussed the role of industry within Canada’s health policy landscape and how organizations such as IMC engage with governments to support the development and accessibility of innovative medicines. IMC works to champion policies that encourage the discovery, development, and delivery of transformative pharmaceuticals to Canadians. Through this work, the organization aims to ensure that patients are able to access new and innovative treatments. 

Building on this foundation, we explored several key topics, including the elements that make up strong government relations skills and the Canadian drug access pathway. Our discussion also highlighted programs designed to accelerate public drug coverage and better align it with private coverage rates. In addition, we examined the financial and budgeting considerations required to support these initiatives and the broader implications they carry for the pharmaceutical sector. 

The conversation also provided valuable insight into how policy decisions and market dynamics outside of Canada, particularly in the United States, can influence the timing and accessibility of new medicines in Canada. Through case studies and real-world examples, Jacqueline, Agata, and Alex illustrated the complex considerations involved in bringing innovative treatments to patients while balancing regulatory, financial, and policy factors. 

We are very thankful for the opportunity to partner with IMC and greatly appreciate the thoughtful discussion and insights shared by Jacqueline, Agata, and Alex. Conversations like these help deepen our understanding of how different sectors contribute to Canada’s policy landscape and the collaborative efforts required to support innovation and patient access across the country.